Lilly’s Mounjaro Cuts Risk of Heart Attacks, Strokes in Study

Eli Lilly's Mounjaro, in its largest and longest trial to date, achieved non-inferiority to the older drug Trulicity in preventing major cardiovascular events like heart attacks and strokes, yet did not demonstrate superior efficacy as anticipated. This outcome positions Mounjaro as a comparable option for cardiovascular risk reduction, but tempers expectations for incremental benefits beyond its established indications.

Analysis

A head-to-head trial of Eli Lilly & Co.’s (LLY) Mounjaro against its older drug, Trulicity, successfully demonstrated non-inferiority in reducing major cardiovascular events. While meeting this primary endpoint confirms Mounjaro as an acceptable alternative, the outcome falls short of market expectations, which had anticipated a demonstration of superiority. This result, reflected in the slightly negative sentiment for LLY, means the drug failed to establish a clear clinical advantage over its predecessor on the cardiovascular front. For Eli Lilly, this tempers a key potential growth narrative for Mounjaro, as it does not provide a compelling new reason for physicians to prefer it over Trulicity solely for its heart-protective benefits, even though its efficacy in diabetes and weight loss remains a core value driver.

Key Decisions for Investors

• Investors should recalibrate growth expectations for Mounjaro, as the lack of cardiovascular superiority over Trulicity may limit its ability to capture market share based on this specific clinical dimension.
• Monitor physician prescribing patterns and formulary decisions, as this non-inferiority result could make payers less willing to grant premium status to Mounjaro over the older, established Trulicity for cardiovascular risk reduction.
• While the news is a modest setback, LLY's core thesis remains largely intact based on Mounjaro's primary indications; however, any valuation premium based on anticipated cardiovascular superiority may now be subject to downward revision.